Skip to content

CG Oncology CGON Book value per share

Book value per share at other companies

Pfizer logo
PfizerPFE
$15.72-0.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$33.20+3.0%
Gilead Sciences logo
Gilead SciencesGILD
$18.75+23.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.85-22.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$3.75+93.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$2.73+80.4%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Calculated from CG Oncology’s reported figures.

Based on the most recent quarter.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's book value per share?
CG Oncology (CGON) reported book value per share of $12.92 in Q1 2026.
How has CG Oncology's book value per share changed year-over-year?
CG Oncology's book value per share increased by 39.6% year-over-year, from $9.25 to $12.92.
What is the long-term trend for CG Oncology's book value per share?
Over 2 years (2023 to 2025), CG Oncology's book value per share has grown at a -41.5% compound annual growth rate (CAGR), from -$28.42 to $9.74.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.